Accessibility StatementSkip Navigation ST. LOUIS, Nov. 20, 2025 /PRNewswire/ -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the fourth fiscal quarter and fiscal year ended September 30, 2025. Highlights: *For additional information regarding non-GAAP measures, such as Adjusted EBITDA, Adjusted net earnings, Adjusted diluted earnings per common share and segment Adjusted EBITDA, see the related explanations presented under "Use of Non-GAAP Measures" ...

Company Overview - Liquidity Services is a leading global provider of e-commerce marketplaces and software solutions powering the Circular Economy[8] - The company has completed over $15 billion in transactions with over 6 million registered buyers[15] - The company serves over 15,000 trusted clients worldwide[15] Financial Performance - The company's annual Gross Merchandise Volume (GMV) has increased from $1145 million in FY22 to $1571 million in FY25[63] - The company's annual revenue has increased from $315 million in FY23 to $477 million in FY25[67] - The company's annual Non-GAAP Adjusted EBITDA has increased from $459 million in FY23 to $608 million in FY25[69] Segment Performance - GovDeals segment GMV reached $2523 million in Q3FY25[41] - RSCG segment GMV reached $1098 million in Q1FY25[47] - Machinio & Software Solutions revenue reached $54 million in Q4FY25[56] Marketplace Growth - AllSurplus marketplace experienced over 30% YoY GMV Growth in the heavy equipment category in Q4-FY25[38] - Liquidationcom marketplace experienced 30% Annual GMV growth in FY25[38] - The company surpassed $15 billion in cumulative GMV[39]

Our management uses these non-GAAP metrics as measures of operating performance to assist in comparing performance from period to period on a consistent basis and to identify business trends related to the company's results of operations. Our management believes these financial performance measurements are also useful because these measures adjust for certain costs and other events that management believes are not representative of our core business operating results. Thus, they provide supplemental informa ...

Eltek (NasdaqCM:ELTK) Q3 2025 Earnings Call November 18, 2025 09:00 AM ET Company ParticipantsRon Freund - CFOEli Yaffe - CEOConference Call ParticipantsMark Sergustanski - AnalystNone - AnalystOperatorLadies and gentlemen, thank you for standing by. Welcome to the Eltek Ltd 2025 Third Quarter Financial Results Conference Call. All participants are at present in a listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session. For operator assist ...

Core Insights - Brady Corporation reported a 7.5% increase in sales for the first quarter of fiscal 2026, reaching $405.3 million compared to $377.1 million in the same quarter last year [2][4] - The company experienced a 16.5% increase in income before income taxes, amounting to $68.5 million, and a net income of $53.9 million, up from $46.8 million in the previous year [3][4] - Adjusted diluted earnings per share (EPS) rose by 8.0% to $1.21, reflecting strong organic sales growth and improved gross profit margins [5][6] Financial Performance - Sales increased by 7.5%, driven by a 2.8% organic sales growth, a 3.2% increase from acquisitions, and a 1.5% boost from foreign currency translation [2][6] - By region, sales in the Americas & Asia rose by 9.6%, while Europe & Australia saw a 3.6% increase, with organic sales growth of 4.7% in the Americas & Asia and a decline of 0.8% in Europe & Australia [2][20] - Net income for the quarter was $53.9 million, with diluted EPS increasing to $1.13 from $0.97 in the same quarter last year [4][6] Adjusted Financial Metrics - Adjusted income before income taxes was $73.8 million, a 7.6% increase compared to the previous year [3][26] - Adjusted net income reached $58.0 million, compared to $54.2 million in the same quarter last year [4][26] - The company raised its adjusted diluted EPS guidance for the fiscal year ending July 31, 2026, from a range of $4.85 to $5.15 per share to $4.90 to $5.15 per share [6][7] Strategic Developments - The acquisition of Mecco at the beginning of the quarter is expected to enhance Brady's laser marking system product line, complementing the previous acquisition of Gravotech [5] - The company maintains a net cash position of $66.8 million, allowing for continued strategic investments and shareholder returns through dividends and share buybacks [5][6] Cash Flow and Guidance - Cash flow from operating activities increased by 42.5% to $33.4 million compared to $23.4 million in the same quarter last year [6] - The fiscal 2026 guidance includes an estimated income tax rate of approximately 21%, depreciation and amortization expense of about $44 million, and capital expenditures of around $40 million [8]

Financial Performance - Record Attributable free cash flow of $251.7 million was achieved in Q3 2025[12] - Adjusted earnings reached $181.0 million, or $0.48 per share[13] - The company has a strong financial position with $1.7 billion in Total Available Liquidity[14] Production Results - Attributable silver production was 5.5 million ounces in Q3 2025[12] - Attributable gold production was 183.5 thousand ounces in Q3 2025[12] Costs - Silver Segment AISC was $15.43 per ounce in Q3 2025[12] - Gold Segment AISC was $1,697 per ounce in Q3 2025[12] Operational Updates - Successful integration of the 44% interest in Juanicipio mine[12] - Increased attributable 2025 silver production guidance and reduced Silver Segment AISC guidance[12] - Discovery of multiple high-grade silver zones at La Colorada[14]

Financial Data and Key Metrics Changes - The company reported record revenue of $104.3 million for Q3 2025, a significant increase of $77.5 million year-over-year [18][19] - Net income reached $108.6 million, translating to $1.26 per diluted share, a substantial improvement from a net loss of $2.8 million in Q3 2024 [21][22] - Adjusted EBITDA for Q3 2025 was $71.8 million, up from a loss of $2 million in the same quarter last year [22][23] - The company raised its full-year revenue guidance from a minimum of $375 million to a range of $390-$410 million [7][8] Business Line Data and Key Metrics Changes - DefenCath sales accounted for $88.8 million of the total revenue, reflecting strong performance and utilization growth [18][19] - The Melinta portfolio contributed approximately $15.5 million in revenue for September 2025, with $12.8 million from Melinta portfolio sales [19] Market Data and Key Metrics Changes - The company anticipates a total addressable market of over $2 billion for Rezeo, aimed at immune-compromised patients undergoing antifungal prophylaxis [10][11] - The total addressable market for DefenCath in the prevention of CLABSI for TPN patients is estimated at up to $750 million [11] Company Strategy and Development Direction - The acquisition of Melinta Therapeutics is seen as transformational, creating a diversified specialty pharmaceutical company with a broad portfolio [5][7] - The company is focusing on integrating operations and capturing approximately $30 million of projected synergies from the Melinta acquisition by the end of 2025 [5][21] - Future growth strategies include expanding DefenCath's utilization and engaging with Medicare Advantage payers [9][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained future profitability, supported by a substantial tax benefit of $59.7 million [22] - The company is optimistic about the operational performance in Q4 2025, expecting significant cash generation and a year-end cash position of approximately $100 million [24] Other Important Information - The integration of CorMedix and Melinta operations is progressing faster than expected, with all functional areas fully integrated from a personnel standpoint [16][17] - The company is working on real-world evidence studies to demonstrate the effectiveness of DefenCath in reducing infection rates [16][40] Q&A Session Summary Question: Inventory stocking versus utilization for DefenCath in Q3 - Management indicated that smaller customers held an average of two to three weeks of inventory, while larger customers held three to four weeks [29] Question: Guidance for next year and potential seasonality - Management noted that there is no historic seasonality in hemodialysis, and they are still assessing the full-year outlook for 2026 [30][31] Question: Real-world evidence and pricing negotiations for post-TDAPA - Management clarified that real-world evidence will be most applicable for Medicare Advantage, which is not bound by post-TDAPA pricing [33] Question: Utilization and patient demographics for LDO - Management reported that utilization is higher than the initial target of 6,000 patients, primarily among fee-for-service patients [38] Question: Pricing dynamics for DefenCath in Q3 - Management acknowledged slight price erosion quarter-over-quarter but emphasized that volume growth has offset these changes [56]

Investor Presentation Where Intelligence Meets Infrastructure® November 11, 2025 Non-GAAP Measures In an effort to provide investors with additional information regarding the Company's results as determined by accounting principles generally accepted in the United States ("GAAP"), the Company also provides non-GAAP information that management believes is useful to investors. These non-GAAP measures have limitations as analytical tools, and securities analysts, investors and other interested parties should n ...

Q3 2025 Financial Performance - Revenue increased to $269 million, a $8 million or 3% increase compared to Q3 2024[8] - Gross profit increased to $68 million, a $23 million or 51% increase compared to Q3 2024[8, 10] - Operational EBITDA significantly increased by $28 million to $29 million, a 2800% increase compared to Q3 2024[10] - Adjusted Operational EBITDA increased by $24 million to $27 million, an 800% increase compared to Q3 2024[10] YTD September 2025 Financial Performance - Revenue increased slightly to $779 million, a $2 million or 0% increase compared to YTD 2024[12] - Gross profit increased to $165 million, a $13 million or 9% increase compared to YTD 2024[12] - Operational EBITDA increased by $23 million to $40 million, a 135% increase compared to YTD 2024[12] - Adjusted Operational EBITDA increased by $21 million to $39 million, a 117% increase compared to YTD 2024[12] Advanced Materials and Chemicals (AM&C) - AM&C revenue increased by 15% compared to the prior year quarter[9] Kodak U.S. Retirement Income Plan - Expected proceeds from reversion increased from $500 million to $600 million, consisting of approximately $450 million in cash and $150 million in hedge funds[8]

3Q Investor Presentation Earnings Summary November 5, 2025 1 This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will," "may" or words of similar meaning and include, but are not limited to, statements regarding the outlook for the company's future business and financial performan ...